Background
Spinal Muscular Atrophy (SMA) is one of the most common recessive
disorders for which several life-saving treatment options are currently
available. It is essential to establish universal SMA screening and
diagnostic programs using scalable, cost-effective and accessible platforms
to accurately identify all variation types, which is complicated by
homologousSMN1andSMN2genes.
Methods
We developed a dual-mode PCR-based target enrichment that generates 2.7
to 11.2 kb amplicons
spanningSMN1andSMN2genes
for any-length nanopore sequencing. We trained a variant calling model that
utilizes paralog-specific sequences and read-depth data to accurately detect
sequence and copy number variants specific to each gene.
Results
We present results from the development, optimization, and external
evaluation of this assay using over 750 samples, including cell lines,
residual presumed normal blood donors, and patients with
knownSMN1andSMN2genotypes.
The assay detects SNVs, indels, and CNVs with >98% accuracy across all
sample sets, with a highly dynamic throughput range, relatively fast
turnaround time, and limited hands-on-time. Together with the modest capital
investment and consumable costs per sample, this assay can help increase
access to SMA testing in low- and middle-income settings.
Conclusion
We describe a PCR/Nanopore sequencing assay and a customized analysis
pipeline for the comprehensive and accurate detection of variation at the
SMA locus and demonstrate its scalability, cost-effectiveness, and potential
for the universal implementation of SMA screening and diagnostic
programs.
Human Genes
SMN1survival of motor neuron 1, telomeric
HGNC:11117SMN2survival of motor neuron 2,
centromeric HGNC:11118CFTRCF transmembrane
conductance regulator HGNC:1884